Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 3,667 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: sample collection Clear all
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 27, 2026, 5:28 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)

NCT05568420
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 49 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Completed No phase listed Observational Results available

COVID-19 Screening Program

NCT05216627
View directory record Official record
Conditions
COVID-19
Interventions
Self-administered saliva-based viral testing
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 27, 2026, 5:28 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic Cancer

NCT06744595
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Biospecimen Collection, Educational Intervention, Electronic Health Record Review, Genetic Counseling, Genetic Testing for Cancer Risk, Survey Administration
Procedure · Other · Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Completed No phase listed Observational

Preoperative Dietary Fat Consumption and Baseline Inflammatory Markers

NCT07442981
View directory record Official record
Conditions
Fat Consumption, Inflammatory Markers
Interventions
Inflammatory markers test in blood prior to surgery, Inflammatory markers test in CSF (cerebrospinal fluid), MOCA test, CAM-3D
Diagnostic Test
Lead sponsor
Ohio State University
Other
Eligibility
60 Years and older
Enrollment
62 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Completed No phase listed Observational

Acquiring Convalescent Specimens for COVID-19 Antibodies

NCT04342195
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, Corona Virus Infection
Interventions
Blood draw
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 27, 2026, 5:28 PM EDT
Recruiting No phase listed Observational

Longitudinal Study of Intra-Uterine Growth Restriction

NCT02382601
View directory record Official record
Conditions
IUGR, Pregnancy
Interventions
Ultrasound, MRI, Blood collection, Neurological Function Assessment, Placental Analysis, Measurement of body fat, Pediatric heart ultrasound
Radiation · Procedure · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

NCT04214067
View directory record Official record
Conditions
Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biospecimen Collection, Brachytherapy, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
Procedure · Radiation · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
275
States / cities
Birmingham, Alabama • Clovis, California • Concord, California + 195 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Recruiting No phase listed Observational

ColoCare Study - Colorectal Cancer Cohort

NCT02328677
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 89 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
6
States / cities
Los Angeles, California • Tampa, Florida • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 27, 2026, 5:28 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Alcohol, Breast Cancer, and Metabolism

NCT07779967
View directory record Official record
Conditions
Alcohol Drinking, Ethanol Intoxication, Breastfeeding
Interventions
Low-alcohol level exposure, Breast-pumping time
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Recruiting No phase listed Observational

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT02269592
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, Hematological Malignancies, B-cell Malignancy, Low-grade, Myelodysplastic Syndrome With Low-grade Lesions, IgG Monoclonal Gammopathy of Uncertain Significance, Smoldering Multiple Myeloma, Waldenstrom Macroglobulinemia
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
7
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

NCT04929041
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
169
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Berkeley, California + 129 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Recruiting Phase 1 Interventional

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

NCT04375631
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Undifferentiated Leukemia
Interventions
Cladribine, Cyclophosphamide, Cyclosporine, Cytarabine, Filgrastim, Hematopoietic Cell Transplantation, Mitoxantrone, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Idarubicin, Fludarabine, Multigated Acquisition Scan, Echocardiography Test, X-Ray Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Withdrawn No phase listed Observational

Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity

NCT04580667
View directory record Official record
Conditions
Prostate Cancer
Interventions
Collection of plasma samples
Other
Lead sponsor
DiaCarta, Inc.
Industry
Eligibility
30 Years to 85 Years · Male only
Timeline
2020 – 2023
U.S. locations
5
States / cities
Gainesville, Florida • Jacksonville, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 27, 2026, 5:28 PM EDT
Recruiting Phase 1 Interventional

FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia

NCT07645469
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Echocardiography Test, Lumbar Puncture, Multigated Acquisition Scan, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Recruiting Phase 1 Interventional

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT06622005
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Cxcr1/2 Inhibitor SX-682, Daratumumab and Recombinant Human Hyaluronidase, Carfilzomib, Dexamethasone, Biospecimen Collection, Bone Marrow Aspiration, Echocardiography, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Recruiting Phase 2 Interventional

Informing Oral Nicotine Pouch Regulations to Promote Public Health

NCT06315881
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Biospecimen Collection, Cigarette, Nicotine Oral Pouch, Smokeless Tobacco, Survey Administration, Text Message-Based Navigation Intervention
Procedure · Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes

NCT04769167
View directory record Official record
Conditions
Congenital Heart Disease, Viremia, Virus Diseases, Enterovirus, Enterovirus Infections, Heart Defects, Congenital, Heart Diseases, Prenatal Infection, Diabetes, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy Complications, Prenatal
Interventions
Stool and Blood Specimen Collection, Follow-up Medical Record Review
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 27, 2026, 5:28 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Efficacy of Fecal Immunochemical Test Using Digital Rectal Exam

NCT03013855
View directory record Official record
Conditions
Fecal Immunochemical Test
Interventions
FIT-SOC, FIT-DRE
Device
Lead sponsor
Boston Medical Center
Other
Eligibility
50 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 27, 2026, 5:28 PM EDT
Recruiting No phase listed Observational

Natural History Study of Patients With Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency

NCT03758521
View directory record Official record
Conditions
Succinic Semialdehyde Dehydrogenase Deficiency
Interventions
Transcranial magnetic stimulation (TMS), Magnetic resonance imaging (MRI), Electroencephalogram (EEG), Bio-specimen Collection
Device · Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Not listed No phase listed Observational

Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

NCT01004640
View directory record Official record
Conditions
Leukemia
Interventions
DNA analysis, Southern blotting, cytogenetic analysis, polymerase chain reaction
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
161
States / cities
San Diego, California • San Francisco, California • Lewes, Delaware + 89 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 27, 2026, 5:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of SKY Breath Meditation on Health and Well-being

NCT05523414
View directory record Official record
Conditions
Stress, Stress, Psychological, Stress, Physiological, Anxiety, Mental Well Being, Happiness, Resilience
Interventions
SKY
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Active, not recruiting No phase listed Observational

Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

NCT03057626
View directory record Official record
Conditions
Recurrent Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
5 Years to 50 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
84
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 27, 2026, 5:28 PM EDT
Recruiting Phase 1 Interventional

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

NCT05691517
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, pH Low Insertion Peptide-exatecan Conjugate CBX-12
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 27, 2026, 5:28 PM EDT